Hepatitis D News and Research

RSS
Hepatitis D is a viral infection that causes liver inflammation (swelling of the tissue which occurs due to injury or infection) and damage.
FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

MAVS prion-like proteins are involved in innate immunity: Discovery

MAVS prion-like proteins are involved in innate immunity: Discovery

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex second quarter net loss decreases to $5.3 million

Idera second quarter net loss increases to $6.3 million

Idera second quarter net loss increases to $6.3 million

GenMark Diagnostics second quarter revenues increase to $901,000

GenMark Diagnostics second quarter revenues increase to $901,000

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst second quarter total revenues decrease to $3.7 million

Needle-free nanopatch vaccine delivery system

Needle-free nanopatch vaccine delivery system

Alnylam second quarter revenue decreases to $20.6 million

Alnylam second quarter revenue decreases to $20.6 million

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

ELPA, WHA announce educational program for hepatitis B patients

ELPA, WHA announce educational program for hepatitis B patients

WHO marks first-ever World Hepatitis Day

WHO marks first-ever World Hepatitis Day

Tips to make family vacations less hazardous for kids and parents

Tips to make family vacations less hazardous for kids and parents

Hepatitis on the rise

Hepatitis on the rise

ELPA, WHA to launch PATH B programme for patients with chronic hepatitis B

ELPA, WHA to launch PATH B programme for patients with chronic hepatitis B

OR models verify cost effectiveness of hepatitis B interventions

OR models verify cost effectiveness of hepatitis B interventions

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

MHCC, U of C partner to evaluate 'The Mind Course' for medical students

MHCC, U of C partner to evaluate 'The Mind Course' for medical students

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Hepatitis B immunization for health care students may fall short of current recommendations

Hepatitis B immunization for health care students may fall short of current recommendations

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.